VERV icon

Verve Therapeutics

7.98 USD
-0.18
2.21%
At close Feb 10, 4:00 PM EST
After hours
7.78
-0.20
2.51%
1 day
-2.21%
5 days
1.01%
1 month
44.30%
3 months
24.30%
6 months
71.24%
Year to date
32.78%
1 year
-40.58%
5 years
-75.00%
10 years
-75.00%
 

About: Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol, a root cause of cardiovascular disease. The company views its operations as and manages its business in one operating segment operating exclusively in the United States.

Employees: 255

0
Funds holding %
of 6,831 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

36% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 25

28% more repeat investments, than reductions

Existing positions increased: 60 | Existing positions reduced: 47

4% more funds holding

Funds holding: 166 [Q2] → 172 (+6) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q2] → 2 (+0) [Q3]

3% less capital invested

Capital invested by funds: $383M [Q2] → $372M (-$10.8M) [Q3]

2.6% less ownership

Funds ownership: 93.41% [Q2] → 90.81% (-2.6%) [Q3]

65% less call options, than puts

Call options by funds: $414K | Put options by funds: $1.19M

Research analyst outlook

We haven’t received any recent analyst ratings for VERV.

Financial journalist opinion

Based on 9 articles about VERV published over the past 30 days

Neutral
GlobeNewsWire
1 week ago
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on January 31, 2025, the company granted equity awards to eight new employees, pursuant to the company's 2024 Inducement Stock Incentive Plan, as an inducement material to each new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Neutral
PRNewsWire
1 week ago
Kuehn Law Encourages Investors of Verve Therapeutics, Inc. to Contact Law Firm
NEW YORK , Jan. 31, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Verve Therapeutics, Inc. (NASDAQ: VERV) breached their fiduciary duties to shareholders.  The investigation concerns potential self-dealing.
Kuehn Law Encourages Investors of Verve Therapeutics, Inc. to Contact Law Firm
Neutral
GlobeNewsWire
1 week ago
Verve Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference
BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference on Wednesday, February 5, 2025 at 9 a.m. ET in New York.
Verve Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference
Neutral
Accesswire
2 weeks ago
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Verve Therapeutics, Inc. (VERV) and Encourages Shareholders to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / January 26, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV). Investors who purchased Verve securities prior to August 9, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/VERV.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Verve Therapeutics, Inc. (VERV) and Encourages Shareholders to Learn More About the Investigation
Positive
Zacks Investment Research
2 weeks ago
Verve Therapeutics (VERV) Moves 18.7% Higher: Will This Strength Last?
Verve Therapeutics (VERV) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Verve Therapeutics (VERV) Moves 18.7% Higher: Will This Strength Last?
Neutral
Accesswire
2 weeks ago
Verve Therapeutics, Inc. (VERV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / January 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV). Investors who purchased Verve securities prior to August 9, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/VERV.
Verve Therapeutics, Inc. (VERV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
Neutral
Accesswire
3 weeks ago
Bronstein, Gewirtz & Grossman, LLC Encourages Verve Therapeutics, Inc. (VERV) Shareholders to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESS Newswire / January 19, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV). Investors who purchased Verve securities prior to August 9, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/VERV.
Bronstein, Gewirtz & Grossman, LLC Encourages Verve Therapeutics, Inc. (VERV) Shareholders to Inquire about Securities Investigation
Neutral
Accesswire
3 weeks ago
Bronstein, Gewirtz & Grossman, LLC Is Investigating Verve Therapeutics, Inc. (VERV) And Encourages Shareholders to Connect
NEW YORK CITY, NY / ACCESSWIRE / January 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV). Investors who purchased Verve securities prior to August 9, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/VERV.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Verve Therapeutics, Inc. (VERV) And Encourages Shareholders to Connect
Neutral
Accesswire
4 weeks ago
Bronstein, Gewirtz & Grossman, LLC Encourages Verve Therapeutics, Inc. (VERV) Stockholders to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESSWIRE / January 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV). Investors who purchased Verve securities prior to August 9, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/VERV.
Bronstein, Gewirtz & Grossman, LLC Encourages Verve Therapeutics, Inc. (VERV) Stockholders to Inquire about Securities Investigation
Neutral
Accesswire
1 month ago
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Verve Therapeutics, Inc. (VERV) and Encourages Investors to Learn More About the Investigation
NEW YORK CITY, NY / ACCESSWIRE / January 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV). Investors who purchased Verve securities prior to August 9, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/VERV.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Verve Therapeutics, Inc. (VERV) and Encourages Investors to Learn More About the Investigation
Charts implemented using Lightweight Charts™